



Recommended Schedule for Administering Doses of PCV13¹ (Pneumococcal Conjugate Vaccine for Children aged 2 Months through 18 Years)

Age at this visit	Vaccination History: Total number of PCV7 and/or PCV13 doses previously received	Recommended PCV13 Dose(s) ²
2-6 months	0 doses	3 doses, 8 weeks apart; 4 th dose at age 12-15 months
	1 dose	2 doses, 8 weeks apart; 4 th dose at age 12-15 months
	2 doses	1 dose, 8 weeks after the last dose; 4 th dose at age 12-15 months
7-11 months	0 doses	2 doses, 8 weeks apart 3 rd dose at 12-15 months
	1 or 2 doses before age 7 months	1 dose at age 7-11 months; 2 nd dose at age 12-15 months (at least 8 weeks later)
12-23 months	0 doses	2 doses, at least 8 weeks apart
	1 dose before age 12 months	2 doses, at least 8 weeks apart
	1 dose at/after age 12 months	1 dose, at least 8 weeks after the last dose ³
	2 or 3 doses before age 12 months	1 dose, at least 8 weeks after the last dose ³
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 dose, at least 8 weeks after the last dose ³
Healthy Children 24-59 months	Any incomplete schedule	1 dose, at least 8 weeks after the last dose ³
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 dose, at least 8 weeks after the last dose ⁴
High Risk Children 24-71 months⁵	Any incomplete series of 2 <u>or</u> less doses	2 doses, one at least 8 weeks after the last dose & another dose at least 8 weeks later
	Any incomplete series of 3 doses	1 dose, at least 8 weeks after the last dose
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 dose, at least 8 weeks after the last dose ⁴
High Risk Children 6-18 years⁶	Whether or not any previous doses of PCV7 or PPSV23 were given	If no previous dose of PCV13, give one dose, at least 8 weeks after any previous doses of PCV7 or PPSV23

¹ Pneumococcal Conjugate Vaccine 13; Prevnar 13™, Wyeth (a subsidiary of Pfizer)

² Minimum intervals between doses is 8 weeks except for children vaccinated at ages less than 12 months, then the minimum interval is 4 weeks

³ No additional PCV13 doses are indicated for children ages 12 through 23 months who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age 12 months or older.

⁴ A single supplemental dose of PCV13 given at least 8 weeks after the last dose of PCV7 is recommended for all children 14 through 59 months of age who have received 4 doses of PCV7 or other age-appropriate, complete PCV7 schedule (fully vaccinated with PCV7). For children who have underlying medical conditions, a supplemental dose is recommended through 71 months of age.

⁵ Children ages 24-71 months in one of the following risk groups

- Immunocompetent: chronic heart and lung disease, diabetes, cerebrospinal fluid leaks, cochlear implants
- Immunocompromised: HIV, chronic renal failure or nephrotic syndrome, or diseases associated with immunosuppressive chemotherapy or radiation therapy including neoplasms, leukemia, lymphomas or solid organ transplant.
- Sickle cell disease and other hemoglobinopathies; congenital or acquired asplenia or splenic dysfunction.

⁶ For children ages 6 through 18 years with functional or anatomic asplenia, including sickle cell disease, HIV infection or other immunocompromising condition, cochlear implant or CSF leak